Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01614990 · ClinicalTrials.gov registry record · Phase 2
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
A Phase 2 study of Cancer Cachexia, sponsored by Garcia, Jose M., MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01614990: Completed Phase 2 study of Cancer Cachexia, sponsored by Garcia, Jose M., MD, PhD.
NCT01614990 is a Phase 2 study of Cancer Cachexia that has completed, run by Garcia, Jose M., MD, PhD. The registered enrollment target is 15 participants, below the 139-participant average among 6 other Cancer Cachexia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01614990, a Phase 2 study of Cancer Cachexia, has completed, sponsored by Garcia, Jose M., MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.
Primary Outcome
The change of body weight(kg)will be measured between day 1 and day (Day 7-Day 1).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Macimorelin
Study Locations (1)
Washington
- Veterans Affairs Puget Sound Health Care System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-05 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
What the finished NCT01614990 record still lists
NCT01614990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 139-participant average among 6 other Cancer Cachexia trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Cancer Cachexia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01614990 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01614990 about?
NCT01614990 is a clinical study titled "Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia". The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.
What is the current status of trial NCT01614990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2012-05. Estimated completion is 2021-12.
What conditions does trial NCT01614990 study?
This clinical trial studies the following conditions: Cancer Cachexia.
What interventions are being tested in trial NCT01614990?
The interventions under investigation include: Placebo (DRUG), Macimorelin (DRUG).
Who is sponsoring clinical trial NCT01614990?
This trial is sponsored by Garcia, Jose M., MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01614990 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Cachexia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
RECRUITING · Phase 2
-
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia
COMPLETED · Phase 2
-
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
COMPLETED · Phase 2
-
A First-in-Human Study of FID-022 in Solid Tumor Patients
RECRUITING
-
Florida Pancreas Collaborative Next Generation Biobank
ACTIVE NOT RECRUITING
-
Vitamin D for Muscle Metabolic Function in Cancer Cachexia
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia